Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Q-linea AB's Net Cash per Share or its related term are showing as below:
CHIX:QLINEs'
s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.09 Med: 10.93 Max: 49.83
Current: 2.37
During the past 11 years, the highest Price-to-Net-Cash Ratio of Q-linea AB was 49.83. The lowest was 2.09. And the median was 10.93.
CHIX:QLINEs's Price-to-Net-Cash is ranked better than 87.81% of 279
companies
in the Medical Devices & Instruments industry
Industry Median: 9.79
vs CHIX:QLINEs: 2.37
Q-linea AB (CHIX:QLINEs) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Q-linea AB Net Cash per Share Related Terms
Q-linea AB Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Q-linea AB's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:QLINES vs ABT, SYK, MDT: Net Cash per Share Comparison
For the Medical Devices subindustry, Q-linea AB's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q-linea AB Price-to-Net-Cash vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Q-linea AB's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Q-linea AB's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Q-linea AB's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-linea AB (CHIX:QLINES) has a Net Cash per Share of kr7.74 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Q-linea AB and its competitors. According to the industry distribution chart, Q-linea AB ranks #34 out of 279 companies in the Medical Devices & Instruments industry, placing it in the top 12.2%.
Is Q-linea AB's Net Cash per Share too high?
Q-linea AB's current Net Cash per Share is kr7.74. Based on the distribution chart, Q-linea AB ranks #34 out of 279 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Q-linea AB has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does Q-linea AB's Net Cash per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Q-linea AB ranks #34 out of 279 companies for Net Cash per Share. This places Q-linea AB in the top 12% of its industry — outperforming the majority of peers. The industry median Net Cash per Share is 9.79. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Medical Devices & Instruments company?
The median Net Cash per Share among Medical Devices & Instruments companies is 9.79, based on 279 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Q-linea AB and its competitors. For the Medical Devices & Instruments industry, the median Net Cash per Share is 9.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Q-linea AB's current Net Cash per Share is kr7.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-linea AB stock overvalued right now?
Q-linea AB (CHIX:QLINES) has a current Net Cash per Share of kr7.74. The stock's GF Value™ is kr1,678.44, compared to a current price of kr1,610.00 — trading 4.1% below its estimated fair value. The current Net Cash per Share is kr7.74. Q-linea AB's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Q-linea AB (CHIX:QLINES), the current Net Cash per Share is kr7.74 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Q-linea AB (CHIX:QLINES) Overvalued in 2026?
Based on GuruFocus' analysis, Q-linea AB stock appears to be undervalued.
The current stock price of kr1,610.00 is trading 4.1% below its estimated GF Value™ of kr1,678.44.
Key valuation signals for CHIX:QLINES:
Net Cash per Share: kr7.74
GF Value™: kr1,678.44 vs. price of kr1,610.00 (4.1% below fair value)
No single metric tells the full story. See the CHIX:QLINES stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Q-linea AB is a company that develops infection diagnostics solutions that benefit patients, healthcare providers, and society, enabling rapid diagnosis of blood infections such as sepsis within six hours of a positive blood culture. It focuses on developing instruments and consumables that benefit patients, healthcare providers, and society. It develops and delivers solutions for healthcare providers, enabling them to diagnose and treat infectious diseases in the shortest possible time. The company's product, ASTar, is a fully automated instrument (AST, antibiotic susceptibility testing), which produces a sensitivity profile from a positive blood culture.
67GF Score
Get the complete analysis for CHIX:QLINES
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:QLINES has been successfully added to your 
